- Opening Session
Opening Remarks by the Committee Chairperson
- Keynote Speech
- Session I • Annex 1 and CCS Implementation
Welcome Remarks by the Moderator
- Fast Release of Sterile Primary Packaging Containers Using a Rapid Microbial Method: Case Study
- Coffee Break at the Exhibition Hall
- Moving Forward on Direction to Continuous and Real-Time Environmental Monitoring for Aseptic Filling
Marc Glogovsky
Marc Glogovsky
Business Unit Manager at Valsource IncMarc Glogovsky is currently a senior consultant and manager of the microbiology division with ValSource, Inc. In his current role, he is focusing on development of contamination control strategies, implementation of rapid microbiological methods (RMMs), and establishing risk-based environmental monitoring programs.
More information about speaker
Marc has been an active PDA member since 2000 and is currently serving on both the Science and ATMP Advisory Boards and as co-chair of the Microbiology/EM Interest Group. He has co-chaired and contributed to several Technical Reports and Points to Consider documents.
Marc earned his B.S. in Biology from Monmouth University and his M.S. in Microbiology & Molecular Genetics from Rutgers University.
- Case Study on Aseptic Process Control Considering Annex 1
Hyun Cheol (Charles) KimThe presentation will focus on Hanmi’s experience in operating an Aseptic Manufacturing Process for prefilled syringe production within Fill and Finish products. It will also discuss control strategies used for aseptic process in prefilled syringe production from an industry perspective. The presentation will feature case presentations on how the company improved its existing operating system in response to the revised regulations of the EU Annex 1. The hardware required to build a Contamination Control System and the direction of improving the operating system will also be discussed. In addition, case studies on investigation and CAPA activities against deviations experienced during RABS operations for aseptic process control will be presented.
Hyun Cheol (Charles) Kim
Vice President and Head of Plant, Pyeongtaek Bio Plant at Hanmi Pharm. Co., Ltd.
- Panel Discussion and Q&A
Marc Glogovsky•Hyun Cheol (Charles) KimMarc Glogovsky
Business Unit Manager at Valsource IncMarc Glogovsky is currently a senior consultant and manager of the microbiology division with ValSource, Inc. In his current role, he is focusing on development of contamination control strategies, implementation of rapid microbiological methods (RMMs), and establishing risk-based environmental monitoring programs.
More information about speaker
Marc has been an active PDA member since 2000 and is currently serving on both the Science and ATMP Advisory Boards and as co-chair of the Microbiology/EM Interest Group. He has co-chaired and contributed to several Technical Reports and Points to Consider documents.
Marc earned his B.S. in Biology from Monmouth University and his M.S. in Microbiology & Molecular Genetics from Rutgers University.Hyun Cheol (Charles) Kim
Vice President and Head of Plant, Pyeongtaek Bio Plant at Hanmi Pharm. Co., Ltd.Hyun Cheol (Charles) Kim has over 25 years of experience in the field of quality and manufacturing operation for both biopharmaceuticals and synthetic pharmaceuticals. He has extensive experience in operating QMS to produce clinical and commercial pharmaceuticals through his involvement in new drug development processes at LG Life Sciences (now LG Chem.) and Hanmi Pharm. He participated in the construction process of a new plant and set up the GMP operating system and through this, gained a deep understanding of GMP operation for plant facilities and utilities. He serves as an instructor in QMS and GMP operation training programs and advisory group at the Ministry of Food and Drug Safety (MFDS) and Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) to share industry opinions and experiences.
More information about speaker
- Lunch Break
- Session II • Aseptic Processing • Techniques, Technologies & Updates
Welcome Remarks by the Moderator
- PDA ANSI Standard Approach to Quality Risk Management in Aseptic Processing
Ivy Louis
Ivy Louis
Founder of Vienni Training and ConsultingIvy Louis is the Founder of VIENNI TRAINING & CONSULTING LLP, holds a Master's degree in Pharmaceutical Sciences and an MBA in Human Resource Management.
More information about speaker
Ivy's combined 33 years spanning across teaching, pharmaceutical manufacturing/quality, and service provider experience is distilled into the consultative and educational approaches that her organization-VIENNI Training & Consulting LLP has been delivering from 2010 onwards. The areas of support for pharmaceutical and biopharmaceutical operations rests on building excellence through consulting in parenteral operations and catering to the learning requirements for operating personnel through training & education.
Ivy has been associated with PDA Inc.(www.pda.org) from 2003, as a member. She has been extremely active in spearheading the activities of the Parenteral Drug Association Chapter in India, from 2013 onwards. Ivy has been contributing in the various capacities as a PDA India Chapter Board member between 2013-2019. She has also been a Member of the Steering Committee for Awards in 2017, Member of the Steering Committee for the PDA letter Editorial Committee and a member of the Task Force that is working on an ANSI standard for Quality Risk Management for Aseptic Processing. She is also a member of the Science Advisory Board for PDA Inc.
- Implementation of PUPSIT to Comply with Annex 1
Wayne Lee
Wayne Lee
Fast Trak™ Validation Services Leader, Global at CytivaWayne has more than 23 years of combined experience in the pharmaceutical and biopharmaceutical, R&D, and manufacturing industry. He has broad experience in pharmaceutical synthetic chemistry unit operations, as well as biologics downstream processing.
More information about speaker
He is currently the Global GM for Fast-TrakTM Validation Services, for Cytiva. Prior to his current role, he has spent more than 13 years in Pall Biotech; in roles of increasing responsibilities. His previous tenure includes Global Head of Validation and Laboratory Operations; Head of APAC (+China) technical support (MS&T); and BioProcess (MS&T) leader for ASEAN. Earlier, he has mixed experience from the Singapore Polytechnic, Merck Sharp & Dohme (Global Technical Operations); Galileo Pharmaceuticals and the Port of Singapore.
He was one of the founding board members of the PDA Singapore Chapter; current board member of the Singapore Chapter, previous board member of the UK Chapter and life-member of the Singapore National Institute of Chemistry (SNIC).
He is a seasoned practitioner of multiple Danaher Business system (DBS) tools; fluent in PSP, DM, SLXII, and is working towards Certified Practitioner (CP) for TPI, and is CP for VS 2.0. He holds a Ph.D. (Organic Chemistry; National University of Singapore) and an M.B.A. (Strategic and Operations Management; University of Bradford); and Double Bachelor’s Degree (Honors and Merit; Chemistry; National University of Singapore).
- Airflow Visualization; Smoke Studies
Morgan Polen
Morgan Polen
Contamination Control Expert at MicroriteMorgan Polen is a subject matter expert on contamination control, airflow visualization, and particle monitoring in cleanrooms with over 35 years of industry experience.
More information about speaker
He is a member of the ISO Technical Committee 209 (Cleanrooms and Associated Controlled Environments) and a board member of IEST and has been instrumental in drafting and editing international cleanroom standards and best practices. He has extensive experience in working on cleanroom projects in the United States, Canada, Mexico, Germany, Malaysia, Taiwan, South Korea, Singapore, Thailand, China, Philippines, India, and Turkey and is a valuable resource in addressing contamination control in critical environments for the electronics, aerospace and healthcare industries.
As a key member of Microrite’s Expert Contamination Control team, Morgan is instrumental in the development of proactive contamination control strategies through pragmatic risk assessment, troubleshooting contamination issues, and helping with FDA 483/warning letter remediation activities.
- A Case Study on Visual Inspection Improvement based on FDA’s Draft Guidance
- Evolution of Aseptic-Containment in Biological and ATMP product filling
- Panel Discussion and Q&A
Wayne Lee•Ivy Louis•Morgan PolenWayne Lee
Fast Trak™ Validation Services Leader, Global at CytivaWayne has more than 23 years of combined experience in the pharmaceutical and biopharmaceutical, R&D, and manufacturing industry. He has broad experience in pharmaceutical synthetic chemistry unit operations, as well as biologics downstream processing.
More information about speaker
He is currently the Global GM for Fast-TrakTM Validation Services, for Cytiva. Prior to his current role, he has spent more than 13 years in Pall Biotech; in roles of increasing responsibilities. His previous tenure includes Global Head of Validation and Laboratory Operations; Head of APAC (+China) technical support (MS&T); and BioProcess (MS&T) leader for ASEAN. Earlier, he has mixed experience from the Singapore Polytechnic, Merck Sharp & Dohme (Global Technical Operations); Galileo Pharmaceuticals and the Port of Singapore.
He was one of the founding board members of the PDA Singapore Chapter; current board member of the Singapore Chapter, previous board member of the UK Chapter and life-member of the Singapore National Institute of Chemistry (SNIC).
He is a seasoned practitioner of multiple Danaher Business system (DBS) tools; fluent in PSP, DM, SLXII, and is working towards Certified Practitioner (CP) for TPI, and is CP for VS 2.0. He holds a Ph.D. (Organic Chemistry; National University of Singapore) and an M.B.A. (Strategic and Operations Management; University of Bradford); and Double Bachelor’s Degree (Honors and Merit; Chemistry; National University of Singapore).Ivy Louis
Founder of Vienni Training and ConsultingIvy Louis is the Founder of VIENNI TRAINING & CONSULTING LLP, holds a Master's degree in Pharmaceutical Sciences and an MBA in Human Resource Management.
More information about speaker
Ivy's combined 33 years spanning across teaching, pharmaceutical manufacturing/quality, and service provider experience is distilled into the consultative and educational approaches that her organization-VIENNI Training & Consulting LLP has been delivering from 2010 onwards. The areas of support for pharmaceutical and biopharmaceutical operations rests on building excellence through consulting in parenteral operations and catering to the learning requirements for operating personnel through training & education.
Ivy has been associated with PDA Inc.(www.pda.org) from 2003, as a member. She has been extremely active in spearheading the activities of the Parenteral Drug Association Chapter in India, from 2013 onwards. Ivy has been contributing in the various capacities as a PDA India Chapter Board member between 2013-2019. She has also been a Member of the Steering Committee for Awards in 2017, Member of the Steering Committee for the PDA letter Editorial Committee and a member of the Task Force that is working on an ANSI standard for Quality Risk Management for Aseptic Processing. She is also a member of the Science Advisory Board for PDA Inc.Morgan Polen
Contamination Control Expert at MicroriteMorgan Polen is a subject matter expert on contamination control, airflow visualization, and particle monitoring in cleanrooms with over 35 years of industry experience.
More information about speaker
He is a member of the ISO Technical Committee 209 (Cleanrooms and Associated Controlled Environments) and a board member of IEST and has been instrumental in drafting and editing international cleanroom standards and best practices. He has extensive experience in working on cleanroom projects in the United States, Canada, Mexico, Germany, Malaysia, Taiwan, South Korea, Singapore, Thailand, China, Philippines, India, and Turkey and is a valuable resource in addressing contamination control in critical environments for the electronics, aerospace and healthcare industries.
As a key member of Microrite’s Expert Contamination Control team, Morgan is instrumental in the development of proactive contamination control strategies through pragmatic risk assessment, troubleshooting contamination issues, and helping with FDA 483/warning letter remediation activities.
- Coffee Break at the Exhibition Hall
- Session III • Cell & Gene Therapy
Welcome Remarks by the Moderator
- Korea's ATMP Regulation’s Requirements, Scope, and Characteristics: How Are They Different from the EU and US?
Heonho Jung
Heonho Jung
Associate Director of Novartis KoreaHeonho Jung is an associate director in Global Cell Therapy Operations department at Novartis, Seoul, Korea.
More information about speaker
He had diverse experience from several quality roles, Microbiology analyst/QC analyst/Site CSV coordinator/QA manager/Certified QA Auditor/Quality Head of Korea local operating Company, during working for several multinational pharmaceutical companies, MSD/ Novartis V&D/Johnson and Johnson/GSK CH, for 20 years.
With GMP experiences, he also had a unique role as a biosafety officer at Institute of Pasteur Korea managing BSL 2/3 labs and QMS of Biosafety. Recently he has a role to perform on-boarding activities and continuously overseeing CAR-T cell therapy processes for the first approved CAR-T product’s sites in Korea after 2021.
Heonho Jung has a master’s degree in microbiology from Pusan National University and a bachelor degree in Chemical Engineering.
- ICH Q5A Revision: Quality Control Through Viral Contamination Risk Mitigation for Monoclonal Antibodies Drugs, Gene Therapies and Beyond
Dr. Alison Armstrong
Dr. Alison Armstrong
Senior Director and Global Head of the Technical and Scientific Solutions at MerckDr. Alison Armstrong is Senior Director and Global Head of the Technical and Scientific Solutions team. She established a client facing scientific consultancy team in 2015. This team is responsible for scientific and regulatory advice and fully supports customers worldwide. Dr. Armstrong has authored a number of articles on trends in biosafety testing and is a member of regulatory taskforce groups related to rapid technologies. She is an invited speaker at global conferences.
More information about speaker
Dr. Armstrong holds a PhD in Molecular Virology from the University of Glasgow
- Optimization of Aseptic Manufacturing Risk Mitigation Strategies for ATMPs
Richard Denk
Richard Denk
Senior Consultant Aseptic Processing & Containment at Skan AGRichard Denk is working at SKAN AG, headquartered in Allschwil Switzerland as a Senior Consultant Aseptic Processing & Containment. Richard is Member of the PDA ATMP Advisory Board and chairs the PtC of the Manufacturing of ATMPs. Richard also chaired the 2022 PDA ATMP Conference in Brussels and is a Member of the Program Committee of the PDA 2022 Annex 1 workshops. Richard is a member of the PDA Isolator Expert Group and publisher of the PDA Paper “Isolator Surfaces and Contamination Risk to Personnel and Patient”. Furthermore, Richard is member of the ISPE Annex 1 and PIC/s Annex 2A commenting group. Richard is a global recognized subject matter expert on Containment and has developed the containment pyramid.
More information about speaker
- Panel Discussion and Q&A
Dr. Alison Armstrong•Heonho JungDr. Alison Armstrong
Senior Director and Global Head of the Technical and Scientific Solutions at MerckDr. Alison Armstrong is Senior Director and Global Head of the Technical and Scientific Solutions team. She established a client facing scientific consultancy team in 2015. This team is responsible for scientific and regulatory advice and fully supports customers worldwide. Dr. Armstrong has authored a number of articles on trends in biosafety testing and is a member of regulatory taskforce groups related to rapid technologies. She is an invited speaker at global conferences.
More information about speaker
Dr. Armstrong holds a PhD in Molecular Virology from the University of GlasgowHeonho Jung
Associate Director of Novartis KoreaHeonho Jung is an associate director in Global Cell Therapy Operations department at Novartis, Seoul, Korea.
More information about speaker
He had diverse experience from several quality roles, Microbiology analyst/QC analyst/Site CSV coordinator/QA manager/Certified QA Auditor/Quality Head of Korea local operating Company, during working for several multinational pharmaceutical companies, MSD/ Novartis V&D/Johnson and Johnson/GSK CH, for 20 years.
With GMP experiences, he also had a unique role as a biosafety officer at Institute of Pasteur Korea managing BSL 2/3 labs and QMS of Biosafety. Recently he has a role to perform on-boarding activities and continuously overseeing CAR-T cell therapy processes for the first approved CAR-T product’s sites in Korea after 2021.
Heonho Jung has a master’s degree in microbiology from Pusan National University and a bachelor degree in Chemical Engineering.
- Networking Reception
- Session IV • Human Error Reduction and Quality Improvement in Aseptic Environment, Part I
Welcome Remarks by the Moderator
- MFDS inspection lessons learned or trend/example
Yeonhae Han, MFDS
- Quality Management Maturity Guidelines
Michael CutterMaking quality improvements in aseptic operations requires a way of thinking that leads to efficient and highly reliable supplies of products. This presentation looks firstly at the ‘Why’ adopting a higher level of maturity benefits all stakeholders and then covers the ‘How’ to make the change. Finally, the presentation will show ‘What’ a Quality Management Maturity Model looks like in practice. As the US FDA prepares to publish its current thinking of QMM, there are equally important drivers to embarking on growing your maturity model.
Michael Cutter
Chief Quality Officer at Biocon Biologics ltd
- Quality Maturity Model / Quality Improvement & Learning From Recent Inspections
Peter Qiu
Peter Qiu
External Advocacy Lead China at Roche GenentechDr. Peter Qiu is the External Advocacy Lead China at Roche Genentech with over 13 years of experience working with the US FDA. He was the Division Director in the Division of Biotechnology Manufacturing, Office of Pharmaceutical Manufacturing Assessment, CDER. He led the assessment of manufacturing processes, facilities, and microbiological control for CDER’s Biologics License Application review and inspection program.
More information about speaker
Dr. Qiu has extensive knowledge in microbial controls and sterility assurance assessment as well as in pre-license and pre-approval inspections for biotech products.
Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences.
- Panel Discussion and Q&A
Michael Cutter•Peter QiuMichael Cutter
Chief Quality Officer at Biocon Biologics ltdMichael is a highly experienced Quality professional having spent more than 30 years in the pharma and biotech industry. He is currently the Chief Quality Officer at Biocon Biologics Limited and prior to that was head of Connected Health and Head of Pharma Quality at Merck KGaA before which he spent 5 years at Novartis remediation Warning Letters and launching new products. Michael has extensive global experience and has lead capacity building projects with the WHO in India and the European Union in the ASEAN region.
More information about speakerPeter Qiu
External Advocacy Lead China at Roche GenentechDr. Peter Qiu is the External Advocacy Lead China at Roche Genentech with over 13 years of experience working with the US FDA. He was the Division Director in the Division of Biotechnology Manufacturing, Office of Pharmaceutical Manufacturing Assessment, CDER. He led the assessment of manufacturing processes, facilities, and microbiological control for CDER’s Biologics License Application review and inspection program.
More information about speaker
Dr. Qiu has extensive knowledge in microbial controls and sterility assurance assessment as well as in pre-license and pre-approval inspections for biotech products.
Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences.
- Coffee Break at the Exhibition Hall
- Session V: Human Error Reduction and Quality Improvement, Part II
Welcome Remarks by the Moderator
- Knowledge, Skills, and Experiences: Competencies for a Sterility Assurance Professional
Arthur Dumba
Arthur Dumba
Director and General Manager of The Society for Sterility Assurance Professionals (SfSAP)Arthur Dumba is a Radiation Sterilization consultant and has been supporting various healthcare companies across Europe and the USA in gamma, electron beam and X-ray processing, and dosimetry. Arthur is an initial founder of the Society for Sterility Assurance Professionals (SfSAP), and with the support of the International Irradiation Association (iia), AAMI, ASTM and PDA. SfSAP is leading the initiative to provide a competency framework and career development pathway for those involved in the field of sterility assurance. Arthur has over 25 years of healthcare industry knowledge and over 15 Years Irradiation and Sterilization experience and knowledge. He is a member of ASTM E61 on Radiation Processing and an iia contributor member.
More information about speaker
- A Pathway for Competency Development for Sterilization as a Subject
James Vesper (Virtual)
James Vesper (Virtual)
Director of ValsourceJames Vesper, PhD, MPH designs and develops instructional courses and workshops for the pharmaceutical and biopharma industries and is Director, of Learning Solutions at ValSource, Inc. He has had more than 40 years experience in the pharmaceutical industry.
More information about speaker
Dr. Vesper has written six books, including Root Cause Investigations for CAPA (2020) and multiple technical articles on risk management. He has received the PDA’s Agallico Award for Teaching Excellence and, in 2021, PDA’s Distinguished Author/Editor of the Year. He has also served as a consultant to World Health Organization’s (WHO) Vaccine Quality Network – Global Learning Opportunities and has trained health authority inspectors through WHO and PIC/S in US, Taiwan, London, China, Greece, Turkey and Brazil.
- Human Factor Control Strategy for Aseptic Manufacturing: SB & Virtuosi
Jinwoo Kim
Jinwoo Kim
Compliance Manager at Samsung BioepisJinwoo Kim has over 20 years’ hands-on industrial experience in the Biotech and Pharmaceutical industry, focusing on qualification/validation, quality assurance for drug products, and regulatory compliance. He is currently part of the external / internal audit and GxP regulatory compliance monitoring/improvement at Samsung Bioepis’ Quality Team.
More information about speaker
- Panel Discussion and Q&A
Arthur Dumba•Jinwoo Kim•James Vesper (Virtual)Arthur Dumba
Director and General Manager of The Society for Sterility Assurance Professionals (SfSAP)Arthur Dumba is a Radiation Sterilization consultant and has been supporting various healthcare companies across Europe and the USA in gamma, electron beam and X-ray processing, and dosimetry. Arthur is an initial founder of the Society for Sterility Assurance Professionals (SfSAP), and with the support of the International Irradiation Association (iia), AAMI, ASTM and PDA. SfSAP is leading the initiative to provide a competency framework and career development pathway for those involved in the field of sterility assurance. Arthur has over 25 years of healthcare industry knowledge and over 15 Years Irradiation and Sterilization experience and knowledge. He is a member of ASTM E61 on Radiation Processing and an iia contributor member.
More information about speakerJinwoo Kim
Compliance Manager at Samsung BioepisJinwoo Kim has over 20 years’ hands-on industrial experience in the Biotech and Pharmaceutical industry, focusing on qualification/validation, quality assurance for drug products, and regulatory compliance. He is currently part of the external / internal audit and GxP regulatory compliance monitoring/improvement at Samsung Bioepis’ Quality Team.
More information about speakerJames Vesper (Virtual)
Director of ValsourceJames Vesper, PhD, MPH designs and develops instructional courses and workshops for the pharmaceutical and biopharma industries and is Director, of Learning Solutions at ValSource, Inc. He has had more than 40 years experience in the pharmaceutical industry.
More information about speaker
Dr. Vesper has written six books, including Root Cause Investigations for CAPA (2020) and multiple technical articles on risk management. He has received the PDA’s Agallico Award for Teaching Excellence and, in 2021, PDA’s Distinguished Author/Editor of the Year. He has also served as a consultant to World Health Organization’s (WHO) Vaccine Quality Network – Global Learning Opportunities and has trained health authority inspectors through WHO and PIC/S in US, Taiwan, London, China, Greece, Turkey and Brazil.
- Lunch Break
- Session VI: Drug, Device and Packaging, Part I
Welcome Remarks by the Moderator
- Updates on TR 73-2, Medical Device Regulation , General Safety and Performance Requirement for Prefill Syringes
Bettine BoltresInjectable drug products that are placed on the European market in a prefilled syringe are considered medical devices and thus have to fulfil the “General Safety and Performance Requirements” (GSPRs) (Medical Device Regulation EU 2017/745, Annex I. As these GSPRs have been extended and are applicable to all medical devices, no matter the intended use, there is some lack of clarity in industry on how exactly to apply those to prefilled syringes. This Technical Report suggests how to approach this, which GSPRs are applicable and which supportive information from suppliers can be used to prove compliance.
Bettine Boltres
Director Scientific Affairs & Technical Solutions, Glass Systems of West Pharmaceutical Services
- Collaborating to Simplify Device Development and Characterize Glass Solutions for Auto-Injectors
- Case Study: Autoinjector Assembling and Control Processes
Susanne HallIn this presentation, we could show the thoughts and steps of an autoinjector assembly project, from a CDMO's point of view. Starting with the first scope of the project and the requirements for the process implementation. Depending on the project progress a scale up might be necessary. In parallel, it is very important to implement the controls of the manufacturing process and the final release tests.
The primary packaging material is changing during the development phase? This could have a significant influence on the processing or functionality of the device.
Susanne Hall
Director, Secondary Packaging & AVI Projects of VETTER PHARMA
- Panel Discussion and Q&A
Bettine Boltres•Susanne HallBettine Boltres
Director Scientific Affairs & Technical Solutions, Glass Systems of West Pharmaceutical ServicesAs Director Scientific Affairs & Technical Solutions, Glass Systems, Dr. Bettine Boltres is supporting the scientific exchange between West and the pharmaceutical industry. This is complementing her work as Product Manager for Schott Pharmaceutical Tubing, where she provided scientific consulting for glass primary packaging. Bettine is an active member of the USP Packaging and Distribution Expert Committee, the European Pharmacopoeia Commission Group of Experts 16 (elastomers and plastics) and the GLS Working Party (glass). She is Convenor of the ISO Working Group 4 (Elastomers) and member of the Working Group 2 (glass). Additionally, Bettine is on the PDA Board of Directors and in 2015, she published the book “When Glass Meets Pharma”, which builds the bridge between glass for pharmaceutical primary packaging and drug substances. Dr. Boltres is a (bio)chemist by training, receiving a diploma in chemistry from the University of Frankfurt, Germany and a PhD in biochemistry from the university of Cologne, Germany.
More information about speakerSusanne Hall
Director, Secondary Packaging & AVI Projects of VETTER PHARMASusanne Hall began her career in 1990 at Dr. Karl Thomae in Biberach as Head of Packaging Technology. In 1993, she joined Vetter’s Research and Development department as Head of Packaging Material Incoming Control and in 2008 was named Team Leader of Secondary Packaging. Since 2019, she has been the Director of Secondary Packaging and AVI Projects. In this position, Susanne leads three teams that ensure the implementation of customer products from development to commercial into production. For secondary packaging this includes device assembly, labeling and final packaging as well as implementing tests for a controlled safe process and the meeting of customer expectations. She is also responsible for the transfer of products from manual visual inspection to fully automated inspection lines. Susanne has a diploma in engineering from the College of Engineering where she focused on specialized precision engineering.
More information about speaker
- Coffee Break at the Exhibition Hall
- Session VII: Drug Device and Packaging, Part II
Welcome Remarks by the Moderator
- Exploring the Impact of Injection Molding and Steam Sterilization on Pre-Fillable Cartridge Packaging System Tolerances
- A Novel CCIT Approach to Reach Annex 1 Requirements
- Viral Safety of Cleaned Surfaces for the Presentation
- Panel Discussion and Q&A
- Closing Remarks